版本:
中国

BRIEF-Adaptimmune Therapeutics entered into five-year strategic manufacturing agreement with Percent, unit of Caladrius Biosciences

Sept 19 Adaptimmune Therapeutics

* Entered into five-year strategic manufacturing agreement with Percent, unit of Caladrius Biosciences

* Agreement for supply of co's SPEAR T-cell therapies Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐